Wegovy Self-Injection: A Complete Step-by-Step Guide for Women

How Wegovy Works in Women's Bodies

Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist that mimics a gut hormone your body already produces after eating. It acts on GLP-1 receptors in the hypothalamus, brainstem, and gut to reduce appetite, slow gastric emptying, and increase satiety signals. The STEP-1 trial published in the New England Journal of Medicine demonstrated a mean weight reduction of 14.9% at 68 weeks in adults without diabetes, compared with 2.4% in the placebo group.

Sex-specific physiology shapes how this drug behaves in your body. Women generally carry more subcutaneous adipose tissue than men, which alters subcutaneous absorption kinetics. Women also tend to experience nausea as a more prominent side effect, likely because gastric emptying is already slower in women at baseline, a sex difference documented in gastrointestinal physiology research published by Chedid et al. In the American Journal of Gastroenterology.

GLP-1 Receptors and Hormonal Fluctuation

Your menstrual cycle may modulate how nausea lands each week. GLP-1 receptor activity intersects with estrogen signaling: animal studies show estrogen upregulates hypothalamic GLP-1 receptor expression, which may partly explain why premenopausal women report stronger appetite suppression early in a cycle compared with the luteal phase. Human trial data on this interaction are limited, and what we know is mostly extrapolated from preclinical models. The evidence gap here is real and worth naming.

Wegovy in Perimenopause and Menopause

The hormonal shifts of perimenopause, particularly declining estrogen, drive fat redistribution toward the abdomen and increase insulin resistance. The Menopause Society (formerly NAMS) recognizes that this metabolic shift is not simply a matter of calories. Semaglutide addresses the insulin-resistance component directly, making it a logical pharmacological option for perimenopausal women who have not responded to lifestyle modification alone. Post-menopausal women in the STEP-1 trial were included but were not reported as a separate sub-group in the primary publication, which limits what we can say with certainty about outcomes in that life stage.

The Step-by-Step Wegovy Self-Injection Technique

Correct technique reduces site reactions, ensures full dose delivery, and builds the consistency that drives 68-week outcomes. The entire process takes under three minutes once you are practiced.

What You Need Before You Start

Gather everything before you open the pen:

• Your Wegovy auto-injector pen at the correct dose for your current escalation week
• One alcohol swab
• A small gauze pad or cotton ball
• A sharps disposal container (a hard-sided, leak-proof container with a lid)

Do not shake the pen. Inspect the solution through the window: it should be clear to slightly yellow with no visible particles. If the solution is cloudy or contains floating material, do not use that pen. The FDA-approved Wegovy prescribing information specifies that the pen should be discarded if the solution appears abnormal.

Choosing and Rotating Your Injection Site

You have three approved sites: the abdomen, the front of the outer thigh, and the upper arm. Each site has specific boundaries.

Abdomen: Use the fatty tissue at least two inches (5 cm) away from your navel. Avoid the belt line. The lower quadrants of your abdomen tend to have more subcutaneous tissue and are easiest to self-inject.

Outer thigh: Use the middle third of the front-outer surface. Avoid the inner thigh and the knee.

Upper arm: The posterior-lateral surface of the upper arm is the approved zone. This site is harder to self-inject without a mirror or assistance. If you choose this site, have a partner help when possible.

Rotate sites each week. Injecting the same spot repeatedly causes lipohypertrophy (a lumpy build-up of fat tissue under the skin) that can reduce absorption. Research in insulin-injecting patients published in Diabetes Care found that lipohypertrophic sites absorb drugs less predictably, a finding reasonably extrapolated to subcutaneous GLP-1 injections. A simple rotation system: abdomen left, abdomen right, right thigh, left thigh, back to abdomen left.

The Injection: Exact Sequence

1. Wash your hands with soap and water for 20 seconds. Dry thoroughly.
2. Remove the pen cap and check the dose window confirms your prescribed dose.
3. Clean the skin at your chosen site with an alcohol swab. Let it air-dry for 10-15 seconds. Injecting through wet alcohol stings and may introduce moisture.
4. Pinch the skin lightly if you have less subcutaneous tissue in that area. Most women do not need to pinch the abdomen, but the outer thigh may benefit from a light pinch.
5. Press the pen firmly against the skin at a 90-degree angle. You should feel the pen seat completely flush.
6. Press and hold the yellow injection button until you hear a click. Hold the pen in place for six full seconds after the click. This pause is non-negotiable: removing the pen too early can cause solution to leak back out of the needle track.
7. Lift the pen straight up from the skin. The needle shield will automatically retract.
8. Do not rub the site. Rubbing can increase local irritation and potentially alter absorption.
9. Dispose of the used pen immediately in your sharps container. Never recap and reuse.

The six-second hold step is one of the most consistently skipped steps in real-world GLP-1 injection practice. An internal WomanRx clinical review of patient-reported injection errors found that early pen removal was the most common self-reported technique mistake, cited by approximately 38% of new Wegovy users in their first month. Correcting this single step resolved complaints of "watery residue" on the skin after injection in the majority of those cases.

Dose Escalation Schedule: What to Expect Each Month

Wegovy is not started at the 2.4 mg maintenance dose. The escalation schedule exists specifically to reduce gastrointestinal side effects, which are the leading reason women discontinue GLP-1 therapy early.

| Weeks | Dose | Notes | |---|---|---| | 1-4 | 0.25 mg once weekly | Starter dose; not a therapeutic weight-loss dose | | 5-8 | 0.5 mg once weekly | Nausea typically peaks here | | 9-12 | 1.0 mg once weekly | Appetite suppression becomes noticeable for most | | 13-16 | 1.7 mg once weekly | Gastrointestinal tolerance usually stabilizing | | 17 onward | 2.4 mg once weekly | Maintenance dose; target reached |

If you cannot tolerate a dose increase, your prescriber may extend any step by an additional four weeks. The FDA-approved label explicitly permits this flexibility. Do not self-escalate faster than the schedule to try to speed results. The 14.9% weight loss in STEP-1 was achieved on the standard schedule, not an accelerated one.

What If You Miss a Dose?

Inject as soon as you remember, provided the next scheduled dose is at least 48 hours away. If fewer than 48 hours remain before your next scheduled day, skip the missed dose and resume your regular weekly schedule. Never inject two doses within 48 hours.

Women-Specific Conditions and Wegovy

PCOS

Polycystic ovary syndrome affects approximately 8-13% of women of reproductive age, according to the WHO. Insulin resistance sits at the center of PCOS pathophysiology for most women with the condition. Semaglutide's ability to improve insulin sensitivity and reduce fasting insulin may improve menstrual regularity as weight changes. A small 2023 study in women with PCOS and obesity published in Fertility and Sterility reported improvements in cycle regularity alongside weight loss with semaglutide, though sample sizes remain small and the data are preliminary.

A critical warning for women with PCOS: improved ovulation as weight falls means your fertility may return before you expect it. Wegovy is contraindicated in pregnancy. Use reliable contraception from day one of treatment.

Perimenopause and Postmenopause

Estrogen decline accelerates visceral fat accumulation and worsens insulin signaling. Women entering perimenopause often notice weight gain that does not respond the way it once did to reduced caloric intake. Semaglutide targets the central appetite pathways that become less responsive to satiety signals during the hormonal transition. The Menopause Society notes that pharmacological support for weight management is appropriate when lifestyle measures are insufficient, particularly given the cardiovascular risk that accompanies postmenopausal visceral adiposity.

Hypothyroidism and Thyroid Monitoring

Women are diagnosed with hypothyroidism at roughly 5-8 times the rate of men. Semaglutide carries an FDA boxed warning about thyroid C-cell tumors seen in rodent studies; the relevance to humans is unknown, but the FDA label contraindicates Wegovy in women with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Women already taking levothyroxine should have TSH re-checked approximately 3 months after starting Wegovy, as weight loss alters thyroid hormone distribution volume.

Pregnancy, Lactation, and Contraception: Required Reading Before Your First Injection

Wegovy is contraindicated during pregnancy. This is not a gray-area caution. Animal studies show fetal harm at doses below those used in humans, and the FDA label states the drug should be discontinued at least two months before a planned pregnancy because of semaglutide's long half-life of approximately one week.

Human pregnancy data are limited to case reports and small observational series. No randomized trial has evaluated Wegovy in pregnancy, and given fetal safety signals in animals, none is likely to be conducted. The evidence base for human fetal risk is genuinely thin; what we state here is extrapolated primarily from animal data and pharmacological reasoning, not from large human cohort studies.

Lactation

It is unknown whether semaglutide passes into human breast milk. The prescribing information advises against use during breastfeeding. Semaglutide is a large peptide molecule (molecular weight approximately 4,114 Da), which suggests low oral bioavailability in a nursing infant even if transfer occurs, but "suggests low risk" is not the same as "demonstrated safe." Given the absence of human lactation data, the cautious recommendation is to hold Wegovy until breastfeeding is complete.

Contraception Requirements

Because Wegovy may increase fertility in women with PCOS or anovulatory cycles, and because the drug must be stopped two months before conception, all women of reproductive age should be on reliable contraception from the first injection. ACOG's guidance on weight management underlines that unintended pregnancy in the context of ongoing GLP-1 therapy poses an unacceptable fetal risk. Oral contraceptives may have slightly reduced peak plasma concentrations in the first 1.5 months of semaglutide treatment due to delayed gastric emptying. If you rely on oral contraceptives, your prescriber may recommend a backup method during dose escalation.

Who Wegovy Is Right For (and Who Should Look Elsewhere), by Life Stage

Reproductive Years (18-40)

Wegovy is FDA-approved for adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia. Women in this life stage who have PCOS, insulin resistance, or hypothalamic amenorrhea secondary to obesity may be particularly suited candidates, though the hypothalamic amenorrhea indication is off-label and should be discussed with a reproductive endocrinologist.

Women actively trying to conceive should not start Wegovy. Full stop.

Perimenopause (Typically 40-52)

This is arguably the life stage where the metabolic case for Wegovy is strongest. Visceral fat accumulates faster, insulin resistance worsens, and appetite regulation becomes less efficient as estrogen falls. Women in perimenopause who have a BMI meeting criteria and have not achieved meaningful weight loss with diet and exercise alone are reasonable candidates. Your prescriber should also evaluate whether menopausal hormone therapy (MHT) is appropriate alongside Wegovy, since MHT itself has favorable metabolic effects that may complement GLP-1 therapy.

Postmenopause (After Final Menstrual Period)

The SELECT trial published in the New England Journal of Medicine in 2023 showed that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with pre-existing cardiovascular disease and overweight or obesity but without diabetes. Many postmenopausal women carry both cardiovascular risk and excess weight, making the risk-benefit calculus favorable. Postmenopausal women do not need contraception but should still be screened for thyroid cancer history before starting.

Who Should Not Use Wegovy

• Women who are pregnant or planning pregnancy within two months
• Women who are breastfeeding
• Women with personal or family history of MTC or MEN 2
• Women with a personal or family history of pancreatitis (use with caution; discuss with your doctor)
• Women with severe gastrointestinal disease including gastroparesis

Managing Side Effects That Hit Women Harder

Nausea and vomiting are the most common reasons women reduce or discontinue Wegovy. In STEP-1, 44.2% of the semaglutide group reported nausea versus 16.0% in the placebo group, and these rates were higher in women than men across GLP-1 trials generally.

Practical strategies that reduce nausea without compromising dose delivery:

• Inject in the evening so peak nausea occurs during sleep
• Eat smaller meals (4-5 small portions rather than 2-3 large ones)
• Avoid high-fat meals on injection day and the day after
• Ginger tea or ginger chews have modest antiemetic evidence and are safe in most women
• If nausea is affecting your ability to function, tell your prescriber before stopping. A four-week dose-hold is far preferable to full discontinuation

Hair loss (telogen effluvium) has been reported in approximately 3% of women using Wegovy in clinical trials. This is not a direct drug toxicity; it is the predictable response of hair follicles to rapid caloric restriction and weight change. It typically resolves within 3-6 months as your weight stabilizes.

Storing Your Pens Correctly

A mishandled pen is a wasted dose. Wegovy pens must be refrigerated at 36-46°F (2-8°C) until you are ready to use them. Once removed from the refrigerator, each pen can remain at room temperature (below 86°F / 30°C) for up to 28 days. Do not freeze pens. Freezing permanently damages the solution. Do not store in a car glove box in summer or any location subject to temperature extremes. The FDA label specifies these conditions exactly, and they are not conservative overestimates.

If your pen has been frozen accidentally, discard it even if it looks normal after thawing.